$2.25
-0.03(-1.12%)
Mkt Cap $1M
$2.17
$16.32
52-Week Range
At a Glance
AI-generatedFY 2025 was a period of significant operating losses and cash consumption as CNS Pharmaceuticals advanced its clinical programs, with management acknowledging a critical need for future capital to sustain operations and execute its business plan.
8-K
CNS Pharmaceuticals, Inc. entered into an employment agreement with Steve O’Loughlin to serve as Chief Financial Officer effective March 2, 2026, and with Christopher Downs to resign as CFO and serve as Senior Vice President – Finance effective the same date. These changes involve new compensation arrangements including base salaries, bonuses, equity grants, and severance terms.$1M
Market Cap
—
Revenue
-$244M
Net Income
Employees4
Fundamentals
How The Business Makes Money
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001729427
ISINUS18978H5081
CUSIP18978H508
Phone800 946 9185
Address2100 West Loop South, Houston, TX, 77027, US
SEC EDGAR